Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... 2014 (PRWEB) July 23, 2014 ... University. , The goal of the Symposium ... full spectrum of scientists working in the biomaterials ... topics that represent the most promising directions for ...     Provide faculty and government scientists ...
(Date:7/22/2014)... Even within a phylum so full of mean little ... arthropods for its cruelty -- at least to crickets. Native ... is a most predatory sort of parasite. It swoops onto ... of larvae, and leaves its wicked brood to invade, kill ... of this would be possible without the fly,s ability to ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... , June 15 /PRNewswire-Asia/ -- AgFeed Industries, Inc. ... hog production and animal nutrient companies in China , ... the first phase of the Xinyu production pod starting in ... a division of Genus PLC (LSE: GNS). This stocking will ...
... Cellular ... of bringing more relevant and highly predictive toxicity testing to the drug discovery process. ... Madison, ... into a research collaboration with the goal of bringing more relevant and highly predictive ...
... ... the life sciences industry that incorporates distinctive features and functionality , ... (PRWEB) June 15, ... life sciences industry, today announced the release of Version 2.0 of its Interactive ...
Cached Biology Technology:AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 2AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 3AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 4Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 2Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 3Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 3
(Date:7/23/2014)... Currently, no cure exists for Alzheimer,s disease, the ... Americans. But scientists are now reporting new progress ... cancer treatment, that shows promise as a potential ... ACS, Journal of Medicinal Chemistry . , ... that in a healthy brain, the protein known ...
(Date:7/23/2014)... preconditioning has been confirmed by many studies, but ... released in the Neural Regeneration Research ... and co-workers from Tongji Hospital Affiliated to Tongji ... China performed cerebral ischemic preconditioning in rats by ... mechanism underlying the neuroprotective effect of ischemic preconditioning. ...
(Date:7/22/2014)... The exhibit consists of both still images and ... of scientific research. Forty-four still images were chosen ... students, postdocs, staff, and alumni representing more than ... from more than 50 submissions. , Zach Donnell, ... of the 2014 organizers, noted that the exhibit ...
Breaking Biology News(10 mins):Art of Science 2014 2
... 16, 2010 Primary care physicians agree they have a ... the right weight management resources. Obese or heavier adults ... lose weight may lack information about effective weight loss methods ... research commissioned and released today by the Strategies to Overcome ...
... programs to safeguard them from getting out of control ... cancer. Until now, researchers assumed that these protective systems ... first time, using an animal model for lymphoma, cancer ... the Charit University Hospital Berlin in Germany have ...
... to passive smoking are more likely to have health problems ... levels of nucleated red blood cells in the umbilical cord ... and Public Health . Pediatrician Abd ElBaky of the ... Cairo University, Egypt, have found that obesity and passive smoking ...
Cached Biology News:STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 2STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 32 at 1 stroke -- how cells protect themselves from cancer 2Obesity and passive smoking reduce oxygen supply to unborn baby 2
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: